Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 5 | 2016 | 24 | 1.550 |
Why?
|
| Schizophrenia | 2 | 2016 | 45 | 0.870 |
Why?
|
| Polypharmacy | 2 | 2013 | 11 | 0.700 |
Why?
|
| Psychiatry | 2 | 2010 | 27 | 0.630 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 160 | 0.580 |
Why?
|
| Depressive Disorder, Major | 4 | 2010 | 125 | 0.570 |
Why?
|
| Medication Adherence | 1 | 2016 | 46 | 0.530 |
Why?
|
| Bipolar Disorder | 3 | 2013 | 39 | 0.480 |
Why?
|
| Frontotemporal Dementia | 1 | 2013 | 4 | 0.450 |
Why?
|
| Drug Interactions | 3 | 2007 | 77 | 0.410 |
Why?
|
| Metformin | 1 | 2010 | 32 | 0.350 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 105 | 0.330 |
Why?
|
| Hypnosis | 1 | 2009 | 1 | 0.330 |
Why?
|
| Guideline Adherence | 1 | 2010 | 91 | 0.330 |
Why?
|
| Metabolic Syndrome | 1 | 2010 | 77 | 0.330 |
Why?
|
| Overweight | 1 | 2010 | 110 | 0.330 |
Why?
|
| Video Recording | 1 | 2009 | 38 | 0.320 |
Why?
|
| Epilepsy | 1 | 2009 | 32 | 0.320 |
Why?
|
| Mianserin | 1 | 2008 | 1 | 0.310 |
Why?
|
| Anti-Anxiety Agents | 1 | 2008 | 7 | 0.310 |
Why?
|
| Metronidazole | 1 | 2008 | 16 | 0.310 |
Why?
|
| Neutropenia | 1 | 2008 | 35 | 0.300 |
Why?
|
| Electroencephalography | 1 | 2009 | 127 | 0.300 |
Why?
|
| Menopause | 1 | 2007 | 28 | 0.290 |
Why?
|
| Desipramine | 1 | 2007 | 4 | 0.290 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2007 | 4 | 0.290 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2007 | 6 | 0.290 |
Why?
|
| Triazoles | 1 | 2007 | 14 | 0.290 |
Why?
|
| Anti-Infective Agents | 1 | 2008 | 77 | 0.280 |
Why?
|
| Phenytoin | 1 | 2007 | 15 | 0.280 |
Why?
|
| Ranitidine | 1 | 2007 | 9 | 0.280 |
Why?
|
| Delirium | 1 | 2007 | 13 | 0.280 |
Why?
|
| Humans | 15 | 2016 | 26827 | 0.270 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2006 | 27 | 0.260 |
Why?
|
| Clozapine | 1 | 2005 | 1 | 0.260 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 367 | 0.240 |
Why?
|
| Patient Selection | 1 | 2005 | 143 | 0.230 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 205 | 0.220 |
Why?
|
| Female | 8 | 2009 | 14463 | 0.180 |
Why?
|
| Middle Aged | 6 | 2010 | 6818 | 0.170 |
Why?
|
| Body Weight | 2 | 2010 | 246 | 0.140 |
Why?
|
| Male | 6 | 2013 | 12870 | 0.140 |
Why?
|
| Paliperidone Palmitate | 1 | 2016 | 3 | 0.140 |
Why?
|
| Haloperidol | 1 | 2016 | 8 | 0.140 |
Why?
|
| Hospitalization | 1 | 2016 | 189 | 0.120 |
Why?
|
| Aged | 3 | 2013 | 5167 | 0.120 |
Why?
|
| Adult | 4 | 2008 | 7383 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2010 | 918 | 0.120 |
Why?
|
| Pedophilia | 1 | 2013 | 1 | 0.110 |
Why?
|
| Retirement | 1 | 2013 | 11 | 0.110 |
Why?
|
| Burnout, Professional | 1 | 2013 | 19 | 0.110 |
Why?
|
| Antiparkinson Agents | 1 | 2013 | 3 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 8 | 0.110 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 17 | 0.110 |
Why?
|
| Parkinson Disease | 1 | 2013 | 38 | 0.100 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 237 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2013 | 103 | 0.100 |
Why?
|
| HIV Infections | 1 | 2013 | 146 | 0.090 |
Why?
|
| Cyclohexanols | 1 | 2010 | 5 | 0.090 |
Why?
|
| Data Collection | 1 | 2010 | 101 | 0.090 |
Why?
|
| Weight Loss | 1 | 2010 | 72 | 0.080 |
Why?
|
| Antidepressive Agents | 1 | 2010 | 29 | 0.080 |
Why?
|
| Wakefulness | 1 | 2009 | 23 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2010 | 300 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 233 | 0.080 |
Why?
|
| Drug Therapy | 1 | 2008 | 15 | 0.070 |
Why?
|
| Anxiety Disorders | 1 | 2008 | 59 | 0.070 |
Why?
|
| Quetiapine Fumarate | 1 | 2007 | 1 | 0.070 |
Why?
|
| Dibenzothiazepines | 1 | 2007 | 1 | 0.070 |
Why?
|
| Valproic Acid | 1 | 2007 | 15 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2009 | 390 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 42 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 279 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2008 | 263 | 0.070 |
Why?
|
| Postmenopause | 1 | 2007 | 83 | 0.070 |
Why?
|
| Hysterectomy | 1 | 2007 | 80 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 657 | 0.070 |
Why?
|
| Piperazines | 1 | 2007 | 45 | 0.070 |
Why?
|
| Demography | 1 | 2006 | 91 | 0.060 |
Why?
|
| Biotransformation | 1 | 2005 | 9 | 0.060 |
Why?
|
| Obesity | 1 | 2010 | 650 | 0.060 |
Why?
|
| Prevalence | 1 | 2006 | 472 | 0.060 |
Why?
|
| United States | 1 | 2010 | 2033 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 445 | 0.060 |
Why?
|
| Neoplasms | 1 | 2013 | 755 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2010 | 2264 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 586 | 0.060 |
Why?
|
| Sex Factors | 1 | 2005 | 446 | 0.060 |
Why?
|
| Age Factors | 1 | 2006 | 716 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2006 | 1217 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 1927 | 0.050 |
Why?
|
| Smoking | 1 | 2005 | 465 | 0.050 |
Why?
|
| Adolescent | 1 | 2007 | 2957 | 0.040 |
Why?
|
| Desvenlafaxine Succinate | 1 | 2010 | 1 | 0.020 |
Why?
|